Takuma Furitsu
Osaka University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Takuma Furitsu.
Journal of Clinical Investigation | 1993
Takuma Furitsu; Tohru Tsujimura; T Tono; Hirokazu Ikeda; Hitoshi Kitayama; U Koshimizu; Hiroyuki Sugahara; J H Butterfield; L K Ashman; Yoshio Kanayama
The c-kit proto-oncogene encodes a receptor tyrosine kinase. Binding of c-kit ligand, stem cell factor (SCF) to c-kit receptor (c-kitR) is known to activate c-kitR tyrosine kinase, thereby leading to autophosphorylation of c-kitR on tyrosine and to association of c-kitR with substrates such as phosphatidylinositol 3-kinase (PI3K). In a human mast cell leukemia cell line HMC-1, c-kitR was found to be constitutively phosphorylated on tyrosine, activated, and associated with PI3K without the addition of SCF. The expression of SCF mRNA transcript in HMC-1 cells was not detectable by means of PCR after reverse transcription (RT-PCR) analysis, suggesting that the constitutive activation of c-kitR was ligand independent. Sequencing of whole coding region of c-kit cDNA revealed that c-kit genes of HMC-1 cells were composed of a normal, wild-type allele and a mutant allele with two point mutations resulting in intracellular amino acid substitutions of Gly-560 for Val and Val-816 for Asp. Amino acid sequences in the regions of the two mutations are completely conserved in all of mouse, rat, and human c-kit. In order to determine the causal role of these mutations in the constitutive activation, murine c-kit mutants encoding Gly-559 and/or Val-814, corresponding to human Gly-560 and/or Val-816, were constructed by site-directed mutagenesis and expressed in a human embryonic kidney cell line, 293T cells. In the transfected cells, both c-kitR (Gly-559, Val-814) and c-kitR (Val-814) were abundantly phosphorylated on tyrosine and activated in immune complex kinase reaction in the absence of SCF, whereas tyrosine phosphorylation and activation of c-kitR (Gly-559) or wild-type c-kitR was modest or little, respectively. These results suggest that conversion of Asp-816 to Val in human c-kitR may be an activating mutation and responsible for the constitutive activation of c-kitR in HMC-1 cells.
International Archives of Allergy and Immunology | 1995
Tohru Tsujimura; Takuma Furitsu; Masahiro Morimoto; Yoshio Kanayama; Shintaro Nomura; Yuji Matsuzawa; Yukihiko Kitamura; Yuzuru Kanakura
The c-kit protooncogene encodes a receptor tyrosine kinase that mediates signals required for differentiation, proliferation and survival of mast cells. We have already shown the constitutive activation of c-kit receptor tyrosine kinase (KIT) in a human mast cell leukemia line (HMC-1) and a murine mastocytoma cell line (P-815). We here examined whether such constitutive activation of KIT occurred in the rat tumor mast cell line RBL-2H3 as well, which is frequently used as a tool for studying functions of mast cells. In RBL-2H3 cells, KIT was constitutively phosphorylated on tyrosine and activated in the absence of autocrine production of its ligand, stem cell factor (SCF). Sequencing analysis revealed that one of c-kit genes of RBL-2H3 cells had a point mutation, resulting in amino acid substitution of Tyr for Asp in codon 817. When rat wild-type c-kit cDNA and mutant-type c-kit cDNA encoding KITTyr817 were transfected into cells of a human embryonic kidney cell line (293T), only mutant form KITTyr817 was constitutively phosphorylated on tyrosine and activated in the absence of SCF. Since mutations at the same Asp codon constitutively activated KIT in all the human HMC-1, murine P-815, and rat RBL-2H3 cell lines, and since the incorporation of antisense oligonucleotides of c-kit messenger RNA significantly suppressed the proliferation of RBL-2H3 cells, the activating mutations in the Asp codon of the c-kit gene appeared to be involved in neoplastic growth of mast cells.
Annals of Hematology | 1990
Hirosuke Yagura; Toshiharu Tamaki; Takuma Furitsu; Yoshiaki Tomiyama; Tetsuo Nishiura; Nobuhiko Tominaga; Shuichi Katagiri; Takeshi Yonezawa; Seiichiro Tarui
SummaryFunctional and structural characteristics of interleukin 2 (IL-2) receptors on B-cell chronic lymphocytic leukemia (B-CLL) cells were analyzed by a proliferation assay, IL-2 binding assay and cross-linking study. In the3H-thymidine incorporation assay, purified B-CLL cells from four out of sixteen cases, in which the percentage of Tac antigen (Tac Ag) positive cells in peripheral blood lymphocytes ranged from 0 to 48.8%, responded to IL-2 (100 U/ml) after both 3- and 6-day incubation. No relationship was found between the responsiveness to IL-2 and the percentage of Tac Ag positive cells. In the radiolabeled IL-2 binding assay, however, B-CLL cells from all seven cases examined, including three cases with mitogenic response to IL-2 and four cases without mitogenic response, were shown to have both high- and low-affinity receptors. The number of high- and low-affinity receptors per cell ranged from 29–186 and from 420 to 1,800, respectively. Furthermore, with the affinity cross-linking method p55 (Tac Ag) and p70/75 were found even in cases without mitogenic response in their B-CLL cells. In conclusion, the B-CLL cells so far examined possessed high-affinity IL-2 receptors consisting of p55 and p70/75; nevertheless, this was not sufficient to respond to the mitogenic signal of IL-2.
Blood | 1995
Hitoshi Kitayama; Yuzuru Kanakura; Takuma Furitsu; Tohru Tsujimura; Kenji Oritani; Hirokazu Ikeda; Hiroyuki Sugahara; Hideki Mitsui; Yoshio Kanayama; Yukihiko Kitamura
Blood | 1994
Tohru Tsujimura; Takuma Furitsu; Masahiro Morimoto; Koji Isozaki; Shintaro Nomura; Yuji Matsuzawa; Yukihiko Kitamura; Yuzuru Kanakura
Blood | 1992
Yoshitaka Ebi; Yuzuru Kanakura; Tomoko Jippo-Kanemoto; Tohru Tsujimura; Takuma Furitsu; H Ikeda; Shiro Adachi; Tsutomu Kasugai; Shintaro Nomura; Yoshio Kanayama
Leukemia | 1994
Yuzuru Kanakura; Takuma Furitsu; Tohru Tsujimura; Joseph H. Butterfield; Leonie K. Ashman; Hirokazu Ikeda; Hitoshi Kitayama; Yoshio Kanayama; Yuji Matsuzawa; Yukihiko Kitamura
Cancer Research | 1993
Yuzuru Kanakura; Hiroyuki Sugahara; Hideki Mitsui; Hirokazu Ikeda; Takuma Furitsu; Hirosuke Yagura; Hitoshi Kitayama; Yoshio Kanayama; Yuji Matsuzawa
Oncogene | 1994
Uichi Koshimizu; Tohru Tsujimura; Koji Isozaki; Shintaro Nomura; Takuma Furitsu; Yuzuru Kanakura; Yukihiko Kitamura; Yoshitake Nishimune
International Journal of Oncology | 1993
Hitoshi Kitayama; Yuzuru Kanakura; Takuma Furitsu; Hirokazu Ikeda; Seiichi Hirota; Hiroyuki Sugahara; Atsushi Yamatodani; Yoshio Kanayama; Yukihiko Kitamura; Yuji Matsuzawa